Terms: = Cervical cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
5 results:
1. Tislelizumab for cervical cancer: A retrospective study and analysis of correlative blood biomarkers.
Zheng X; Gu H; Cao X; Pan B; Xiang H; Ju M; Xu S; Zheng M
Front Immunol; 2023; 14():1113369. PubMed ID: 36875089
[TBL] [Abstract] [Full Text] [Related]
2. Pretreatment C-Reactive Protein/Albumin Ratio is Associated With Poor Survival in Patients With 2018 FIGO Stage IB-IIA HPV-Positive cervical cancer.
Jiang Y; Gu H; Zheng X; Pan B; Liu P; Zheng M
Pathol Oncol Res; 2021; 27():1609946. PubMed ID: 34992504
[No Abstract] [Full Text] [Related]
3. High neutrophil-to-lymphocyte ratio is a predictor of short-term survival for patients with recurrent cervical cancer after radiation-based therapy.
Taguchi A; Nakajima Y; Furusawa A; Yoshino Y; Takao M; Kashiyama T; Kino N; Yasugi T
J Obstet Gynaecol Res; 2021 May; 47(5):1862-1870. PubMed ID: 33611808
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic value of systemic hemato-immunological indices in uterine cervical cancer: A systemic review, meta-analysis, and meta-regression of observational studies.
Han X; Liu S; Yang G; Hosseinifard H; Imani S; Yang L; Maghsoudloo M; Fu S; Wen Q; Liu Q
Gynecol Oncol; 2021 Jan; 160(1):351-360. PubMed ID: 33092868
[TBL] [Abstract] [Full Text] [Related]
5. [Neuroendocrine differentiated carcinoma of the uterine cervix].
Horn LC; Fischer U; Bilek K
Zentralbl Gynakol; 1996; 118(12):679-83. PubMed ID: 9082707
[TBL] [Abstract] [Full Text] [Related]
